Keros Therapeutics Inc (KROS)
49.36
-0.14
(-0.28%)
USD |
NASDAQ |
Jun 14, 16:00
49.32
-0.04
(-0.08%)
After-Hours: 20:00
Keros Therapeutics Free Cash Flow: -137.18M for March 31, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2024 | -137.18M |
| December 31, 2023 | -126.97M |
| September 30, 2023 | -122.77M |
| June 30, 2023 | -113.01M |
| March 31, 2023 | -105.03M |
| December 31, 2022 | -71.30M |
| September 30, 2022 | -69.23M |
| June 30, 2022 | -59.04M |
| March 31, 2022 | -54.03M |
| Date | Value |
|---|---|
| December 31, 2021 | -63.17M |
| September 30, 2021 | -51.50M |
| June 30, 2021 | -47.80M |
| March 31, 2021 | -39.61M |
| December 31, 2020 | -37.19M |
| September 30, 2020 | -34.65M |
| June 30, 2020 | -26.80M |
| March 31, 2020 | -22.05M |
| December 31, 2019 | -16.00M |
Free Cash Flow Range, Past 5 Years
-137.18M
Minimum
Mar 2024
-16.00M
Maximum
Dec 2019
-66.52M
Average
-56.54M
Median
Free Cash Flow Benchmarks
| Alnylam Pharmaceuticals Inc | 127.82M |
| Biomarin Pharmaceutical Inc | 163.21M |
| Sarepta Therapeutics Inc | -653.88M |
| PTC Therapeutics Inc | -199.47M |
| ADMA Biologics Inc | 15.91M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -44.56M |
| Cash from Investing (Quarterly) | -0.946M |
| Cash from Financing (Quarterly) | 156.80M |
| Free Cash Flow Per Share (Quarterly) | -1.275 |
| Free Cash Flow to Equity (Quarterly) | -45.51M |
| Free Cash Flow Yield | -8.89% |